Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer

Gynecologic Oncology

Volumn 101, Issue 2, 2006, Pages 269-273

  Garuti, Giancarlo ^a   Cellani, Fulvia ^a   Centinaio, Giovanna ^a   Sita, Giulia ^a   Nalli, Giulio ^a   Luerti, Massimo ^a  

^a Lodi Hospital   (Italy)

Author keywords

Breast cancer; Endometrial hyperplasia; Endometrium; Hysteroscopy; Tamoxifen

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG INDUCED CANCER; DRUG SAFETY; DRUG SCREENING; DRUG USE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; MAJOR CLINICAL STUDY; MENOPAUSE; MOLECULAR STABILITY; POLYPECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; THICKNESS; TRANSVAGINAL ECHOGRAPHY; VAGINAL HYSTERECTOMY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 33646435276     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.010     Document Type: Article

References (22)

1. Konefka E.S., Konefka T., and Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat. Rev. 30 (2004) 291-301
2. Stearns V., and Gelmann E.P. Does tamoxifen cause cancer in humans?. J. Clin. Oncol. 16 (1998) 779-792
3. Kim S.Y., Suzuki N., Laxmi S., and Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev. 36 (2004) 199-218
4. Adami H.O., Bergstrom R., Weiderpass E., Persson I., Barlow L., and McLaughlin J.K. Risk for endometrial cancer following breast cancer: a prospective study in Sweden. Cancer Causes Control 8 (2000) 821-827
5. Berlière M., Charles A., Galant C., and Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet. Gynecol. 91 (1998) 40-44
6. Garuti G., Cellani F., Centinaio G., Sita G., Nalli G., and Luerti M. Baseline endometrial assessment before tamoxifen for breast cancer in asymptomatic menopausal women. Gynecol. Oncol. 98 (2005) 63-67
7. Montgomery B.E., Daum G.S., and Dunton C.J. Endometrial hyperplasia: a review. Obstet. Gynecol. Surv. 59 (2004) 368-378
8. Barakat R.R., Gilewski T.A., Almadrones L., Seigo P.E., Venkatraman E., Hudis C., et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J. Clin. Oncol. 18 (2000) 3459-3463
9. Kedar R.P., Bourne T.H., and Powles T.J. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 343 (1994) 1318-1321
10. Veronesi U., Boyle P., Goldhirsch A., Orecchia R., and Viale G. Breast cancer. Lancet 365 (2005) 1727-1741
11. Garuti G., Sambruni I., Colonnelli M., and Luerti M. Accuracy of hysteroscopy in predicting histopathology of endometrium in 1500 women. J. Am. Assoc. Gynecol. Laparosc. 8 (2001) 207-213
12. World Health Organization. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract. 5th ed. (2002), Springer-Verlag, New York 467-500
13. Kurman R.J., Kaminski P.F., and Norris H.J. The behaviour of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients. Cancer 56 (1985) 403-412
14. Horn L.C., Schurrbusch U., Bilek K., Hentschel B., and Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathological analysis in cases with and without progestogen treatment. Int. J. Gynecol. Cancer 14 (2004) 348-353
15. Neven P., DeMuyder X., VanBelle Y., VanHoof I., and Vanderlek G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 351 (1998) 36
16. Rattanachaiyanont M., Angsuwathana S., Techatrisak K., Tanmahasamut P., Indhavivadhana S., and Leerasiri P. Clinical and pathological responses of progestin therapy for not-atypical hyperplasia: a prospective study. J. Obstet. Gynaecol. Res. 31 (2005) 98-106
17. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 98 (2003) 1802-1810
18. Morandi P., Rouzier R., Altundag K., Buzdar A.U., Theriault R.L., and Hortobagyi G. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M.D. Anderson Cancer Center evidence-based approach. Cancer 101 (2004) 1482-1489
19. Duffy S., and Jackson T. Fewer endometrial abnormalities with anastrozole than tamoxifen: endometrial sub-protocol results from the ATAC early breast cancer trial in postmenopausal patients. Ann. Oncol. 13 Suppl 5 (2002) 139 [Abstr]
20. Garrone O., Mezi S., and Occelli M. Reversal of tamoxifen-induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective TVUS study. Ann. Oncol. 14 Suppl. 14 (2003) A22 [Abstr]
21. Morales L., Timmermann D., Neven P., Konstantinovic M.L., Carbonez A., Van Huffel S., et al. Third generation aromatase inhibitors may prevent and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann. Oncol. 16 (2005) 70-74
22. Agorastos T., Vaitsi V., Pantazis K., Efstathiadis E., Vavilis D., and Bontis J.N. Aromatase inhibitor anastrozole foe treating endometrial hyperplasia in obese postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 118 (2005) 239